“…The multidimensional assessment can be further deepened through the evaluation of the impact of comorbidities (e.g., Cumulative Illness Rating Scale for Geriatric Patients [ 15 ]), disability and functional status (e.g., activities of daily living and instrumental activities of daily living scores [ 16 ], Barthel Index [ 17 ]), cognitive status (e.g., Mini Mental State Examination [ 18 ], Montreal Cognitive Assessment [ 19 ], Short Portable Mental Status Questionnaire [ 20 ]), as well as sarcopenia and physical performance. The latter are relevant metrics to assess overall health and predict outcomes and, as such, should be part of a multidimensional evaluation [ 21 , 22 ]. Sarcopenia—the loss of skeletal muscle mass, strength and function [ 23 ]—is a powerful predictor of CVD progression, falls, reduced quality of life, and death in patients with CVD [ 24 , 25 , 26 , 27 , 28 ].…”